Lack of antagonism between abacavir, lamivudine, and tenofovir against wild-type and drug-resistant HIV-1

被引：0
|
作者：
Lanier, ER [1 ]
Hazen, R [1 ]
Ross, L [1 ]
Freeman, A [1 ]
Harvey, R [1 ]
机构：
[1] GlaxoSmithKline Inc, Res Triangle Pk, NC USA
来源：
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES | 2005年 / 39卷 / 05期
关键词：
tenofovir; abacavir; lamivudine; K65R; M184V; in vitro combination activity;
D O I：
暂无
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Potential contributors to the high rate of virologic failure observed for tenofovir, abacavir, and lamivudine include a low genetic barrier to resistance for this regimen and antagonistic drug-drug interactions. To examine the second possibility, we tested combinations of abacavir, tenofovir, and lamivudine against wild-type and drug-resistant HIV-1 in vitro using peripheral blood mononuclear cells and MT4 cells. Antagonistic interactions were not detected for any combination. If the systems examined accurately reflect the in vivo situation, antagonism does not substantially contribute to the poor efficacy of this triple combination.
引用
收藏
页码：519 / 522
页数：4
相关论文
共 50 条
  • [1] Structure-Based Identification of HIV-1 Nucleocapsid Protein Inhibitors Active against Wild-Type and Drug-Resistant HIV-1 Strains
    Mori, Mattia
    Kovalenko, Lesia
    Malancona, Savina
    Saladini, Francesco
    De Forni, Davide
    Pires, Manuel
    Humbert, Nicolas
    Real, Eleonore
    Botzanowski, Thomas
    Cianferani, Sarah
    Giannini, Alessia
    Dasso Lang, Maria Chiara
    Cugia, Giulia
    Poddesu, Barbara
    Lori, Franco
    Zazzi, Maurizio
    Harper, Steven
    Summa, Vincenzo
    Mely, Yves
    Botta, Maurizio
    [J]. ACS CHEMICAL BIOLOGY, 2018, 13 (01) : 253 - 266
  • [2] Lack of a metabolic and antiviral drug interaction between tenofovir, abacavir and lamivudine
    Ray, AS
    Myrick, F
    Vela, JE
    Olson, LY
    Eisenberg, EJ
    Borroto-Esoda, K
    Miller, MD
    Fridland, A
    [J]. ANTIVIRAL THERAPY, 2005, 10 (03) : 451 - 457
  • [3] Synergy against drug-resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination
    Schader, Susan M.
    Colby-Germinario, Susan P.
    Schachter, Jordana R.
    Xu, Hongtao
    Wainberg, Mark A.
    [J]. AIDS, 2011, 25 (13) : 1585 - 1594
  • [4] An Allosteric Modulator of HIV-1 Protease Shows Equipotent Inhibition of Wild-Type and Drug-Resistant Proteases
    Ung, Peter M. -U.
    Dunbar, James B., Jr.
    Gestwicki, Jason E.
    Carlson, Heather A.
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 2014, 57 (15) : 6468 - 6478
  • [5] A theoretical study of the inhibition of wild-type and drug-resistant HIV-1 reverse transcriptase by some thiazolidenebenzenesulfonamide derivatives
    Soto-Morales, Francisco
    Gomez-Jeria, Juan S.
    [J]. JOURNAL OF THE CHILEAN CHEMICAL SOCIETY, 2007, 52 (03): : 1214 - 1219
  • [6] Overcoming drug resistance in HIV-1 chemotherapy:: The binding thermodynamics of Amprenavir and TMC-126 to wild-type and drug-resistant mutants of the HIV-1 protease
    Ohtaka, H
    Velázquez-Campoy, A
    Xie, D
    Freire, E
    [J]. PROTEIN SCIENCE, 2002, 11 (08) : 1908 - 1916
  • [7] HIV-1 Resistance to Islatravir/Tenofovir Combination Therapy in Wild-Type or NRTI-Resistant Strains of Diverse HIV-1 Subtypes
    Cilento, Maria E.
    Wen, Xin
    Reeve, Aaron B.
    Ukah, Obiaara B.
    Snyder, Alexa A.
    Carrillo, Ciro M.
    Smith, Cole P.
    Edwards, Kristin
    Wahoski, Claudia C.
    Kitzler, Deborah R.
    Kodama, Eiichi N.
    Mitsuya, Hiroaki
    Parniak, Michael A.
    Tedbury, Philip R.
    Sarafianos, Stefan G.
    [J]. VIRUSES-BASEL, 2023, 15 (10):
  • [8] HIV-1 reverse transcriptase mutations identified by in vitro selection with tenofovir (TDF) ± abacavir and tenofovir ± lamivudine
    Stone, C
    Ait-Khaled, M
    Craig, C
    Tisdale, M
    [J]. ANTIVIRAL THERAPY, 2002, 7 : S49 - S49
  • [9] Abacavir-Lamivudine versus Tenofovir-Emtricitabine for Initial HIV-1 Therapy
    Sax, Paul E.
    Tierney, Camlin
    Collier, Ann C.
    Fischl, Margaret A.
    Mollan, Katie
    Peeples, Lynne
    Godfrey, Catherine
    Jahed, Nasreen C.
    Myers, Laurie
    Katzenstein, David
    Farajallah, Awny
    Rooney, James F.
    Ha, Belinda
    Woodward, William C.
    Koletar, Susan L.
    Johnson, Victoria A.
    Geiseler, P. Jan
    Daar, Eric S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (23): : 2230 - 2240
  • [10] Interactions of dioxolane thymine triphosphate (DOT-TP) with wild-type and drug-resistant mutant HIV-1 reverse transcriptases
    Murakami, E.
    Basavapathruni, A.
    Bailey, C. M.
    Anderson, K. S.
    Otto, M. J.
    Furman, P. A.
    [J]. ANTIVIRAL THERAPY, 2006, 11 (05) : S161 - S161
12345